Abstract
Background: Many variants detected after Wuhan-Hu-1 reference which were
able to develop the resistance against the neutralizing antibodies
induced by vaccine and may cause false negative results in diagnostic
tests targeting the S gene. The Covid-19 cases are increasing rapidly in
India and the government authorized a new vaccine for restricted use in
emergency situation. Aims: This review discusses about the efficacy,
safety, and economical aspects of vaccines authorized in India.
Materials and methods: Wide-ranging assessment and analysis of
accessible resources on online database. Results: The rAd26-s & rAd5-s
(Gamaleya Research Institute of Epidemiology and Microbiology)
demonstrate high efficacy as well as safety, followed by BBV152 (Bharat
Biotech) and AZD1222 (Oxford AstraZeneca); AZD1222 is more economical
than other two. Conclusion: The main goal of vaccination is to reduce
deaths, protect the health care system and finally disease control, this
is only be possible if more population is vaccinated with locally
available Covid-19 vaccine and self-awareness about the prevention of
disease transmission. Key Words: Covid-19, SARS-CoV-2, Immunization,
Vaccine, Efficacy.